000142085 001__ 142085
000142085 005__ 20240229105143.0
000142085 0247_ $$2doi$$a10.18632/oncotarget.25275
000142085 0247_ $$2pmid$$apmid:29844871
000142085 0247_ $$2pmc$$apmc:PMC5963615
000142085 0247_ $$2altmetric$$aaltmetric:43094923
000142085 037__ $$aDKFZ-2018-02315
000142085 041__ $$aeng
000142085 082__ $$a610
000142085 1001_ $$aMäder, Lisa$$b0
000142085 245__ $$aPericytes/vessel-associated mural cells (VAMCs) are the major source of key epithelial-mesenchymal transition (EMT) factors SLUG and TWIST in human glioma.
000142085 260__ $$a[S.l.]$$bImpact Journals LLC$$c2018
000142085 3367_ $$2DRIVER$$aarticle
000142085 3367_ $$2DataCite$$aOutput Types/Journal article
000142085 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1549879995_32197
000142085 3367_ $$2BibTeX$$aARTICLE
000142085 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142085 3367_ $$00$$2EndNote$$aJournal Article
000142085 520__ $$aEpithelial-to-mesenchymal transition (EMT) is supposed to be responsible for increased invasion and metastases in epithelial cancer cells. The activation of EMT genes has further been proposed to be important in the process of malignant transformation of primary CNS tumors. Since the cellular source and clinical impact of EMT factors in primary CNS tumors still remain unclear, we aimed at deciphering their distribution in vivo and clinico-pathological relevance in human gliomas. We investigated 350 glioma patients for the expression of the key EMT factors SLUG and TWIST by immunohistochemistry and immunofluorescence related to morpho-genetic alterations such as EGFR-amplification, IDH-1 (R132H) mutation and 1p/19q LOH. Furthermore, transcriptional cluster and survival analyses were performed. Our data illustrate that SLUG and TWIST are overexpressed in gliomas showing vascular proliferation such as pilocytic astrocytomas and glioblastomas. EMT factors are exclusively expressed by non-neoplastic pericytes/vessel-associated mural cells (VAMCs). They are not associated with patient survival but correlate with pericytic/VAMC genes in glioblastoma cluster analysis. In summary, the upregulation of EMT genes in pilocytic astrocytomas and glioblastomas reflects the level of activation of pericytes/VAMCs in newly formed blood vessels. Our results underscore that the negative prognostic potential of the EMT signature in the group of diffuse gliomas of WHO grade II-IV does most likely not derive from glioma cells but rather reflects the degree of proliferating mural cells thereby constituting a potential target for future alternative treatment approaches.
000142085 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000142085 588__ $$aDataset connected to CrossRef, PubMed,
000142085 7001_ $$aBlank, Anna E$$b1
000142085 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b2
000142085 7001_ $$aJansong, Janina$$b3
000142085 7001_ $$aBaumgarten, Peter$$b4
000142085 7001_ $$aWirsik, Naita M$$b5
000142085 7001_ $$0P:(DE-HGF)0$$aZachskorn, Cornelia$$b6
000142085 7001_ $$aEhlers, Jakob$$b7
000142085 7001_ $$aSeifert, Michael$$b8
000142085 7001_ $$aKlink, Barbara$$b9
000142085 7001_ $$aLiebner, Stefan$$b10
000142085 7001_ $$aNiclou, Simone$$b11
000142085 7001_ $$aNaumann, Ulrike$$b12
000142085 7001_ $$0P:(DE-HGF)0$$aHarter, Patrick N$$b13
000142085 7001_ $$0P:(DE-He78)3494efbbc54460b109fe9eab0595adda$$aMittelbronn, Michel$$b14$$eLast author$$udkfz
000142085 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.25275$$gVol. 9, no. 35$$n35$$p24041-24053$$tOncoTarget$$v9$$x1949-2553$$y2018
000142085 909CO $$ooai:inrepo02.dkfz.de:142085$$pVDB
000142085 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142085 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142085 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142085 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142085 9141_ $$y2018
000142085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000142085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000142085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000142085 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3494efbbc54460b109fe9eab0595adda$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000142085 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000142085 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x0
000142085 980__ $$ajournal
000142085 980__ $$aVDB
000142085 980__ $$aI:(DE-He78)G380-20160331
000142085 980__ $$aUNRESTRICTED